Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
ParticipantAP
Andera Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $59.8M 1 disclosed · full round size, not this investor’s share